Daniel Griffin: 300,000 Americans Carry Post-Polio Syndrome as US Measles Surpasses 2025 Total

When Mitch McConnell was hospitalized in June 2026 after a fall that left him briefly unconscious, his public statement described "a mild case of pneumonia" and insisted there were "no broken bones, no concussion, no heart attack or stroke." The careful wording concealed more than it revealed. McConnell, now in his 80s, contracted polio as a child — and to Dr. Daniel Griffin, an infectious disease physician at ProHEALTH Care, the episode was a textbook presentation of post-polio syndrome, a condition that affects 25 to 40 percent of polio survivors and currently afflicts an estimated 300,000 Americans. "Pneumonia in a person over 65 carries roughly 10 percent mortality," Griffin noted, speaking on This Week in Virology. "Nothing's mild when we get older."

The McConnell episode is more than a single patient's story. It opens a window onto a largely invisible cohort — 15 to 20 million people worldwide — whose original polio infections occurred decades ago and who now contend with renewed muscle weakness, chronic fatigue, gait instability, swallowing and speaking difficulties, and a heightened vulnerability to pulmonary infections. The condition has no cure, receives minimal research funding, and is absent from most medical school curricula. Yet the number of Americans living with post-polio syndrome today exceeds the annual peak of paralytic polio during the pre-vaccine era — roughly 58,000 cases — by a factor of five.

The Forgotten Long Tail of Polio

Post-polio syndrome emerges 20 to 40 years after the acute infection. No active virus is recovered from patients; the damage is attributed to decades of compensatory stress on neurons and muscles that took over for those destroyed by the original illness. The syndrome is not diagnosed in people who had subclinical or non-paralytic polio, because those original infections were never captured. The result is a surveillance blind spot that Griffin described in blunt terms: the full burden is invisible without a baseline acute-phase diagnosis.

A listener question later in the episode asked whether "Long Polio" exists beyond paralysis. Griffin confirmed that post-polio syndrome is indeed a post-infectious condition with delayed onset — but noted the framing asymmetry. "The term 'Long COVID' was adopted, while post-polio syndrome was never called 'Long Polio,'" he observed. The distinction is not semantic. It shapes which conditions receive research dollars, media attention, and clinical training. "Why are we distinguishing between wild type and vaccine-derived polio? It's still polio. It paralyzes. There will always be post-polio as long as there is polio."

The comparison to Long COVID is instructive and, for Griffin, unavoidable. Both are post-infectious syndromes with delayed onset. Both produce symptoms that routine clinical exams fail to capture. Both affect populations whose original infections may have been mild or undocumented. And both, until very recently, were met with skepticism from parts of the medical establishment.

Long COVID: The Evidence Moves From Subjective to Structural

Two studies published in mid-2026 are changing the conversation about Long COVID by providing tissue-level evidence for complaints that patients have voiced for years.

The first, a prospective cross-sectional study published in Nature Communications, examined non-hospitalized individuals with persistent ocular symptoms lasting three months to three years after COVID-19 infection. Researchers documented near vision disturbances, weakened autonomic pupillary reflexes, degeneration of corneal nerves, and chronic activation of ocular surface dendritic T cells — none of which were visible on a routine eye exam. Proteomic-based diagnostic models achieved 77 to 91 percent accuracy in distinguishing affected patients from controls, implicating T-cell-mediated neuroinflammation as a likely driver.

The second study, appearing in the International Journal of Infectious Diseases, took gastric mucosal biopsies from 12 Long COVID patients and 8 controls. Using immunohistochemistry for the pan-neuronal marker PGP 9.5 and VIP as a cholinergic fiber marker, researchers found a roughly 50 percent reduction in nerve fiber density in both the fundus and antrum. The loss of cholinergic innervation was most pronounced in the fundus, where nerve fiber density measured 2.1 in patients versus 3.9 in controls.

Griffin raised the question that neither study could yet answer: "Is it cause or consequence? We don't know if this caused Long COVID or if Long COVID caused this." The correlation with clinical parameters, however, suggests the denervation may be the structural substrate underlying the dysautonomia and gastrointestinal symptoms that define the condition for many patients. After years of dismissal, Long COVID is acquiring a physical address in the body.

Active Outbreaks: Cyclospora at Triple the Rate, Legionella in Cooling Towers

While post-infectious syndromes play out over decades, acute outbreaks are accelerating in real time across the United States.

Cyclosporiasis cases are running at roughly three times the level recorded during the 2025 season. Michigan leads with 2,640 confirmed cases, followed by Ohio with 661 and New York with 470, approximately 400 of which are concentrated in New York City. Dozens of hospitalizations have been reported. The likely vehicle is fresh bagged lettuce; historical outbreaks have been traced to raspberries and basil. The parasite, Cyclospora cayetanensis, infects only humans, meaning the transmission chain is straightforward — fecal contamination on fresh produce. Deep frying and commercial freezing kill the organism, making the risk specific to raw vegetables. Griffin noted that the CDC alert arrived late relative to the outbreak curve: "weeks go by and then finally they let the doctors know."

Separately, New York City is managing a Legionella cluster on the Upper East Side. As of July 14, 63 cases had been identified — 12 patients currently hospitalized, 40 discharged, and no deaths. Testing of cooling towers in the affected area found 76 towers positive by PCR for Legionella bacteria. All 76 were cleaned within 48 hours. PCR positivity does not distinguish viable bacteria from non-viable fragments, but Griffin called the response appropriately rapid. The organism is endemic in the upstate reservoir water supply and proliferates in warm conditions within cooling towers. Griffin suggested UV sterilizers as a longer-term engineering solution.

Outbreak	Cases (mid-July 2026)	Geographic Concentration	Suspected Vehicle	Status
Cyclosporiasis	2,640 (MI) + 661 (OH) + 470 (NY)	Michigan, Ohio, New York City	Fresh bagged lettuce	3x higher than 2025; dozens hospitalized
Legionella (NYC)	63 total	Upper East Side, NYC	Cooling towers (76 PCR-positive)	12 hospitalized, 0 deaths; towers cleaned

A smaller outbreak of screwworm has also emerged, with 37 cases including infections in pets and dogs. No fly trap detections have been recorded yet. The countermeasure — millions of sterile irradiated male flies released to disrupt breeding — is already underway.

Measles: 2026 Has Already Surpassed All of 2025

The United States measles count stood at 2,250 confirmed cases as of mid-July 2026, compared with 2,242 cases for the entirety of 2025. With roughly five months remaining in the year, the trajectory puts 2026 on track to become the worst year for measles in the US since the 2019 outbreaks that nearly cost the country its elimination status.

The acceleration is visible at the state level. A listener from Virginia reported a local outbreak of 177 cases in a single week, compared with just 5 cases for all of 2025 in the same state. Wastewater analysis at the York River collection site showed elevated viral levels consistent with community transmission. The CDC's official tally at the time Griffin spoke was 2,231 — meaning the number was still climbing even as the episode was being recorded.

The underlying driver is declining childhood vaccination coverage, a trend that has persisted since the pandemic disrupted routine immunization schedules. Unlike cyclosporiasis or Legionella, measles has a highly effective vaccine. The surge is therefore a policy failure, not a scientific one.

Ebola: The Fastest-Growing Outbreak Meets Two New Countermeasures

In the Eastern Democratic Republic of Congo, the Ebola outbreak has been described as the fastest-growing in history, with over 2,000 confirmed cases in the DRC alone and more than 750 deaths. Spillover cases have been documented in Uganda, and one confirmed case has reached France.

Two parallel intervention efforts launched in July 2026 signal how the response toolkit has evolved since the devastating West African epidemic a decade ago.

On the vaccine front, the University of Oxford began a Phase 1 trial of the VD-B vaccine, targeting Bundibugyo ebolavirus — a less common species against which existing vaccines, designed for the Zaire strain, offer no protection. The trial enrolled 50 healthy adults aged 18 to 55 and will assess safety and immune response.

On the treatment front, Gilead Sciences enrolled the first participants on July 14 in EboPEP, a Phase 2/3 trial testing obeldesivir as oral post-exposure prophylaxis. The trial is being conducted in Ituri province, the outbreak's epicenter, by the National Institute for Biomedical Research in Kinshasa with humanitarian partners. Obeldesivir and remdesivir share the same active mechanism — inhibition of the viral RNA-dependent RNA polymerase — but differ in their prodrug chemistry. Remdesivir requires intravenous administration via a phosphoramidate prodrug that bypasses the rate-limiting first phosphorylation step. Obeldesivir is orally bioavailable: a prodrug removed in the stomach releases the active molecule, which must then be triphosphorylated inside cells. The oral route is less efficient biochemically but dramatically simpler to deploy in an outbreak setting where intravenous infusions are logistically prohibitive.

Griffin flagged an apparent contradiction in the US policy response. Under Title 42 and Title 49, the CDC and Department of Homeland Security have implemented a "do not board" process requiring US citizens departing the DRC to spend 21 days outside the affected region before being permitted to return to the United States. This is occurring despite the existence of Ebola treatment centers within the US that are fully capable of managing imported cases. The restriction is easier to implement politically than a quarantine-and-monitor protocol — but it raises questions about whether the US is building walls rather than leveraging its clinical infrastructure.

COVID-19: A Flat Curve, With Caveats

National wastewater surveillance data through July 4 showed a flat curve for COVID-19. Griffin acknowledged, however, that data reliability has eroded as reporting infrastructure atrophied in the post-emergency period. A small "blip" was visible on the multiscale curve, and anecdotal reports of positive antigen tests from Virginia corresponded to elevated wastewater at one collection site but not another. "It's flat, but there's a little blip there. Some areas have cases. Not a lot."

Griffin had not personally seen clinical COVID-19 cases in his practice for "a little while," and no recommendation was offered for a summer 2026 booster. The expectation is an updated vaccine formulation for fall 2026.

The very banality of the update is itself a data point. A virus that dominated global attention for three years now warrants a few sentences in a clinical roundup — even as its long-term sequelae in millions of patients are only beginning to be understood at the tissue level.

Every outbreak in Griffin's clinical update — from post-polio syndrome to Long COVID to measles to Ebola — traces a common arc. The acute phase captures funding, headlines, and policy responses. The long tail, measured in decades and millions of lives, operates almost entirely out of view. Post-polio syndrome affects 300,000 Americans and 15 to 20 million people globally, yet receives a fraction of the research attention directed at Long COVID, which in turn received a fraction of the attention directed at acute COVID-19. For investors in biopharma — where Gilead's obeldesivir trial, Oxford's Ebola vaccine, and the pipeline of Long COVID diagnostics all represent bets on closing this gap — the pattern is both a structural opportunity and a cautionary tale. The market prices acute interventions efficiently. The demand for treatments addressing the long tail of infectious disease is real, vast, and almost entirely unmet.